Literature DB >> 15304470

Feasibility of eliminating ocular Chlamydia trachomatis with repeat mass antibiotic treatments.

Muluken Melese1, Jaya Devi Chidambaram, Wondu Alemayehu, David Chung Lee, Elizabeth H Yi, Vicky Cevallos, Zhaoxia Zhou, Cathy Donnellan, Michael Saidel, John P Whitcher, Bruce D Gaynor, Thomas M Lietman.   

Abstract

CONTEXT: Mass antibiotic administrations for ocular chlamydial infection play a key role in the World Health Organization's trachoma control program. Mathematical models suggest that it is possible to eliminate trachoma locally with repeat mass treatment, depending on the coverage level of the population, frequency of mass treatments, and rate that infection returns into a community after each mass treatment. Precise estimates of this latter parameter have never been reported.
OBJECTIVE: To determine the rate at which chlamydial infection returns to a population after mass treatment and to estimate the treatment frequency required for elimination of ocular chlamydia from a community. DESIGN, SETTING, AND PARTICIPANTS: Longitudinal cohort study of 24 randomly selected villages from the Gurage Zone in Ethiopia conducted February 2003 to October 2003. A total of 1332 children aged 1 to 5 years were monitored for prevalence of ocular chlamydial infection pretreatment and 2 and 6 months posttreatment.
INTERVENTIONS: All individuals older than 1 year were eligible for single-dose oral azithromycin treatment. Pregnant women were offered tetracycline eye ointment. MAIN OUTCOME MEASURES: Prevalence of ocular chlamydial infection, measured by polymerase chain reaction, in children aged 1 to 5 years, in each of 24 villages at each time point was used to estimate the rate of return of infection and the treatment frequency necessary for elimination.
RESULTS: The prevalence of infection was 56.3% pretreatment (95% confidence interval [CI], 47.5%-65.1%), 6.7% 2 months posttreatment (95% CI, 4.2%-9.2%), and 11.0% 6 months posttreatment (95% CI, 7.3%-14.7%). Infection returned after treatment at an exponential rate of 12.3% per month (95% CI, 4.6%-19.9% per month). The minimum treatment frequency necessary for elimination was calculated to be once every 11.6 months (95% CI, 7.2-30.9 months), given a coverage level of 80%. Thus, biannual treatment, already being performed in some areas, was estimated to be more than frequent enough to eventually eliminate infection.
CONCLUSION: The rate at which ocular chlamydial infection returns to a community after mass treatment suggests that elimination of infection in a hyperendemic area is feasible with biannual mass antibiotic administrations and attainable coverage levels.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15304470     DOI: 10.1001/jama.292.6.721

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  52 in total

1.  Elimination of trachoma: are we in danger of being blinded by the randomised controlled trial?

Authors:  H R Wright; J E Keeffe; H R Taylor
Journal:  Br J Ophthalmol       Date:  2006-11       Impact factor: 4.638

2.  Trachoma, antibiotics and randomised controlled trials.

Authors:  B Shapiro; K Dickersin; T Lietman
Journal:  Br J Ophthalmol       Date:  2006-12       Impact factor: 4.638

3.  Topical azithromycin: new evidence?

Authors:  Hannah Kuper; Richard Wormald
Journal:  Br J Ophthalmol       Date:  2007-05       Impact factor: 4.638

4.  What's new in azithromyin?

Authors:  Anthony Solomon; Matthew Burton
Journal:  Community Eye Health       Date:  2004-12

5.  A framework for public health action: the health impact pyramid.

Authors:  Thomas R Frieden
Journal:  Am J Public Health       Date:  2010-02-18       Impact factor: 9.308

6.  Adverse events after mass azithromycin treatments for trachoma in Ethiopia.

Authors:  Berhan Ayele; Teshome Gebre; Jenafir I House; Zhaoxia Zhou; Charles E McCulloch; Travis C Porco; Bruce D Gaynor; Paul M Emerson; Thomas M Lietman; Jeremy D Keenan
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

7.  Trachoma control in two Central Australian Aboriginal communities: a case study.

Authors:  Van C Lansingh; Bickol N Mukesh; Jill E Keeffe; Hugh R Taylor
Journal:  Int Ophthalmol       Date:  2010-04-01       Impact factor: 2.031

8.  Comparison of an rRNA-based and DNA-based nucleic acid amplification test for the detection of Chlamydia trachomatis in trachoma.

Authors:  Jon L Yang; Julius Schachter; Jeanne Moncada; Dereje Habte; Mulat Zerihun; Jenafir I House; Zhaoxia Zhou; Kevin C Hong; Kathryn Maxey; Bruce D Gaynor; Thomas M Lietman
Journal:  Br J Ophthalmol       Date:  2006-10-18       Impact factor: 4.638

9.  Importance of coverage and endemicity on the return of infectious trachoma after a single mass antibiotic distribution.

Authors:  Takele Lakew; Wondu Alemayehu; Muluken Melese; Elizabeth Yi; Jenafir I House; Kevin C Hong; Zhaoxia Zhou; Kathryn J Ray; Travis C Porco; Bruce D Gaynor; Thomas M Lietman; Jeremy D Keenan
Journal:  PLoS Negl Trop Dis       Date:  2009-08-25

10.  When can antibiotic treatments for trachoma be discontinued? Graduating communities in three African countries.

Authors:  Kathryn J Ray; Thomas M Lietman; Travis C Porco; Jeremy D Keenan; Robin L Bailey; Anthony W Solomon; Matthew J Burton; Emma Harding-Esch; Martin J Holland; David Mabey
Journal:  PLoS Negl Trop Dis       Date:  2009-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.